 Maureen Leehey
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 40 | 2021 | 118 | 4.800 |
Why?
| | Tremor | 34 | 2024 | 98 | 4.240 |
Why?
| | Parkinson Disease | 22 | 2024 | 600 | 3.250 |
Why?
| | Ataxia | 26 | 2021 | 69 | 2.950 |
Why?
| | Cannabidiol | 3 | 2024 | 136 | 1.520 |
Why?
| | Trinucleotide Repeat Expansion | 14 | 2022 | 44 | 1.230 |
Why?
| | Antiparkinson Agents | 6 | 2017 | 41 | 0.990 |
Why?
| | Cannabis | 2 | 2024 | 509 | 0.960 |
Why?
| | Heterozygote | 17 | 2016 | 315 | 0.900 |
Why?
| | Cognition Disorders | 9 | 2024 | 538 | 0.870 |
Why?
| | Dronabinol | 3 | 2024 | 247 | 0.860 |
Why?
| | Parkinsonian Disorders | 7 | 2016 | 43 | 0.810 |
Why?
| | Movement Disorders | 5 | 2016 | 69 | 0.720 |
Why?
| | Creatine | 2 | 2017 | 63 | 0.620 |
Why?
| | Cognition | 5 | 2024 | 1266 | 0.610 |
Why?
| | Mutation | 12 | 2021 | 4089 | 0.600 |
Why?
| | Double-Blind Method | 12 | 2024 | 2029 | 0.550 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 461 | 0.530 |
Why?
| | Metabolic Diseases | 1 | 2017 | 114 | 0.480 |
Why?
| | Aged | 52 | 2024 | 25913 | 0.440 |
Why?
| | Trinucleotide Repeats | 7 | 2011 | 31 | 0.440 |
Why?
| | Middle Aged | 58 | 2024 | 35875 | 0.430 |
Why?
| | Cannabinoids | 3 | 2022 | 182 | 0.400 |
Why?
| | Phenotype | 9 | 2026 | 3162 | 0.400 |
Why?
| | Cerebellar Ataxia | 3 | 2006 | 13 | 0.350 |
Why?
| | Severity of Illness Index | 11 | 2021 | 2925 | 0.350 |
Why?
| | Fibromyalgia | 1 | 2011 | 51 | 0.340 |
Why?
| | Point Mutation | 3 | 2007 | 243 | 0.330 |
Why?
| | Male | 62 | 2024 | 72315 | 0.320 |
Why?
| | Humans | 78 | 2026 | 144759 | 0.310 |
Why?
| | Disease Progression | 8 | 2021 | 2847 | 0.310 |
Why?
| | Genetic Carrier Screening | 4 | 2007 | 32 | 0.310 |
Why?
| | DNA Repeat Expansion | 2 | 2006 | 12 | 0.290 |
Why?
| | Levodopa | 5 | 2016 | 41 | 0.280 |
Why?
| | Female | 49 | 2024 | 78271 | 0.270 |
Why?
| | Memory Disorders | 4 | 2018 | 193 | 0.250 |
Why?
| | Central Nervous System Agents | 1 | 2006 | 7 | 0.250 |
Why?
| | Glutamate Decarboxylase | 3 | 2019 | 165 | 0.240 |
Why?
| | Gait Ataxia | 1 | 2005 | 4 | 0.230 |
Why?
| | Guidelines as Topic | 1 | 2007 | 267 | 0.230 |
Why?
| | Dopamine Agents | 2 | 2016 | 22 | 0.230 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2363 | 0.230 |
Why?
| | RNA-Binding Proteins | 6 | 2004 | 462 | 0.220 |
Why?
| | Treatment Outcome | 12 | 2024 | 11679 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 14 | 2016 | 3863 | 0.210 |
Why?
| | Diagnostic Errors | 1 | 2005 | 175 | 0.210 |
Why?
| | Genetic Testing | 6 | 2011 | 478 | 0.200 |
Why?
| | Age of Onset | 9 | 2016 | 551 | 0.200 |
Why?
| | Brain | 15 | 2016 | 2933 | 0.200 |
Why?
| | Neuropsychological Tests | 12 | 2020 | 1134 | 0.200 |
Why?
| | Akinetic Mutism | 1 | 2003 | 3 | 0.190 |
Why?
| | Cerebral Arterial Diseases | 1 | 2003 | 49 | 0.190 |
Why?
| | Menopause | 2 | 2021 | 320 | 0.180 |
Why?
| | Genetic Therapy | 2 | 2017 | 313 | 0.180 |
Why?
| | Inosine | 1 | 2021 | 14 | 0.180 |
Why?
| | Pedigree | 7 | 2008 | 514 | 0.180 |
Why?
| | Dopamine Agonists | 2 | 2014 | 42 | 0.170 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 5 | 0.170 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2021 | 40 | 0.170 |
Why?
| | Uric Acid | 1 | 2021 | 166 | 0.160 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 2 | 0.160 |
Why?
| | Monoamine Oxidase Inhibitors | 2 | 2017 | 20 | 0.160 |
Why?
| | Nootropic Agents | 1 | 2020 | 30 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 151 | 0.160 |
Why?
| | Alleles | 4 | 2016 | 879 | 0.150 |
Why?
| | Sex Factors | 4 | 2011 | 2112 | 0.150 |
Why?
| | Ovary | 1 | 2021 | 228 | 0.150 |
Why?
| | Nerve Tissue Proteins | 6 | 2004 | 592 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 96 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 576 | 0.140 |
Why?
| | RNA, Messenger | 9 | 2018 | 2832 | 0.140 |
Why?
| | Prodromal Symptoms | 1 | 2018 | 21 | 0.130 |
Why?
| | Urine | 1 | 2017 | 62 | 0.130 |
Why?
| | Syndrome | 5 | 2019 | 380 | 0.130 |
Why?
| | Adult | 23 | 2021 | 40449 | 0.130 |
Why?
| | Aged, 80 and over | 12 | 2016 | 8265 | 0.130 |
Why?
| | RNA, Transfer, Lys | 1 | 1995 | 3 | 0.120 |
Why?
| | Neurons | 5 | 2026 | 1640 | 0.120 |
Why?
| | Peripheral Nervous System Diseases | 2 | 2007 | 133 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 225 | 0.120 |
Why?
| | Family Health | 2 | 2007 | 191 | 0.120 |
Why?
| | Connectome | 1 | 2016 | 95 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2019 | 893 | 0.110 |
Why?
| | Dementia | 3 | 2006 | 303 | 0.110 |
Why?
| | Choice Behavior | 1 | 2016 | 177 | 0.110 |
Why?
| | Gene Transfer Techniques | 2 | 2017 | 185 | 0.100 |
Why?
| | Cerebellum | 3 | 2006 | 223 | 0.100 |
Why?
| | Memantine | 1 | 2014 | 18 | 0.100 |
Why?
| | Ubiquinone | 1 | 2014 | 35 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 748 | 0.100 |
Why?
| | Executive Function | 2 | 2009 | 461 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2015 | 372 | 0.100 |
Why?
| | Nerve Net | 1 | 2016 | 285 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 3333 | 0.100 |
Why?
| | Time Factors | 6 | 2020 | 7173 | 0.100 |
Why?
| | Aging | 3 | 2018 | 1966 | 0.090 |
Why?
| | Nucleic Acid Conformation | 1 | 1995 | 726 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2947 | 0.090 |
Why?
| | Multiple Sclerosis | 2 | 2009 | 484 | 0.090 |
Why?
| | Mitochondria | 2 | 1997 | 984 | 0.090 |
Why?
| | DNA Mutational Analysis | 4 | 2007 | 406 | 0.090 |
Why?
| | Intelligence | 5 | 2018 | 112 | 0.090 |
Why?
| | Neurologic Examination | 3 | 2008 | 131 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2007 | 1489 | 0.090 |
Why?
| | Autoantibodies | 1 | 2019 | 1501 | 0.090 |
Why?
| | Spinocerebellar Degenerations | 2 | 2007 | 7 | 0.080 |
Why?
| | Antioxidants | 1 | 2014 | 549 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2017 | 5408 | 0.080 |
Why?
| | Limit of Detection | 2 | 2022 | 97 | 0.080 |
Why?
| | Conversion Disorder | 1 | 2009 | 10 | 0.080 |
Why?
| | Atrophy | 3 | 2005 | 201 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3604 | 0.070 |
Why?
| | Neuroimaging | 1 | 2012 | 289 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2016 | 885 | 0.070 |
Why?
| | Odds Ratio | 1 | 2011 | 1075 | 0.070 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2008 | 3 | 0.070 |
Why?
| | Selegiline | 1 | 2007 | 5 | 0.070 |
Why?
| | Hypokinesia | 1 | 2007 | 11 | 0.060 |
Why?
| | Body Mass Index | 1 | 2016 | 2438 | 0.060 |
Why?
| | Carbidopa | 1 | 2006 | 11 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2007 | 76 | 0.060 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 46 | 0.060 |
Why?
| | Huntington Disease | 1 | 2007 | 61 | 0.060 |
Why?
| | Intranuclear Inclusion Bodies | 1 | 2005 | 4 | 0.060 |
Why?
| | Problem Solving | 1 | 2007 | 156 | 0.060 |
Why?
| | alpha-Synuclein | 1 | 2026 | 46 | 0.060 |
Why?
| | Activities of Daily Living | 1 | 2009 | 441 | 0.060 |
Why?
| | Gene Silencing | 1 | 2007 | 205 | 0.060 |
Why?
| | Prion Diseases | 1 | 2005 | 15 | 0.060 |
Why?
| | Paraparesis, Spastic | 1 | 2005 | 3 | 0.060 |
Why?
| | Memory, Short-Term | 3 | 2018 | 271 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2006 | 167 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2014 | 17066 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2006 | 250 | 0.060 |
Why?
| | Prions | 1 | 2005 | 50 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2026 | 155 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2007 | 255 | 0.050 |
Why?
| | Motor Activity | 3 | 2020 | 721 | 0.050 |
Why?
| | Brain Tissue Transplantation | 1 | 2003 | 19 | 0.050 |
Why?
| | Fetal Tissue Transplantation | 1 | 2003 | 33 | 0.050 |
Why?
| | Astrocytes | 1 | 2005 | 222 | 0.050 |
Why?
| | Health Surveys | 1 | 2005 | 518 | 0.050 |
Why?
| | Subthalamic Nucleus | 2 | 2017 | 83 | 0.050 |
Why?
| | Intellectual Disability | 1 | 2005 | 175 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2006 | 373 | 0.050 |
Why?
| | Verbal Learning | 3 | 2008 | 73 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2026 | 276 | 0.050 |
Why?
| | Seizures | 1 | 2007 | 460 | 0.050 |
Why?
| | Administration, Oral | 2 | 2020 | 847 | 0.050 |
Why?
| | Gyrus Cinguli | 1 | 2003 | 96 | 0.050 |
Why?
| | Caenorhabditis elegans | 1 | 2026 | 337 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2115 | 0.050 |
Why?
| | Guanine | 1 | 2022 | 87 | 0.040 |
Why?
| | Functional Laterality | 1 | 2003 | 241 | 0.040 |
Why?
| | Regression Analysis | 2 | 2018 | 1003 | 0.040 |
Why?
| | Gene Expression | 1 | 2007 | 1490 | 0.040 |
Why?
| | Genetic Background | 1 | 2021 | 16 | 0.040 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 59 | 0.040 |
Why?
| | Eye Movements | 1 | 2021 | 92 | 0.040 |
Why?
| | Kidney Calculi | 1 | 2021 | 45 | 0.040 |
Why?
| | Placebos | 2 | 2014 | 192 | 0.040 |
Why?
| | Treatment Failure | 1 | 2021 | 365 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2021 | 250 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 454 | 0.040 |
Why?
| | Brain Diseases | 1 | 2001 | 152 | 0.040 |
Why?
| | Time and Motion Studies | 1 | 2020 | 28 | 0.040 |
Why?
| | Bell Palsy | 1 | 1999 | 9 | 0.040 |
Why?
| | Fertility | 1 | 2021 | 168 | 0.040 |
Why?
| | Attention | 2 | 2018 | 457 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
| | Animals | 3 | 2026 | 38058 | 0.040 |
Why?
| | Treatment Refusal | 1 | 1999 | 98 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 2021 | 236 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2016 | 1720 | 0.040 |
Why?
| | Educational Status | 2 | 2016 | 467 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2015 | 1047 | 0.040 |
Why?
| | Recovery of Function | 1 | 2003 | 707 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 541 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Mental Processes | 2 | 2008 | 38 | 0.030 |
Why?
| | Parvovirinae | 1 | 2017 | 5 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1997 | 55 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2018 | 264 | 0.030 |
Why?
| | Postural Balance | 1 | 2020 | 240 | 0.030 |
Why?
| | United States | 4 | 2017 | 15966 | 0.030 |
Why?
| | Electron Transport | 1 | 1997 | 118 | 0.030 |
Why?
| | Motivation | 1 | 2001 | 610 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1997 | 273 | 0.030 |
Why?
| | Dependovirus | 1 | 2017 | 79 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5960 | 0.030 |
Why?
| | National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2016 | 6 | 0.030 |
Why?
| | Stroke | 1 | 2005 | 1256 | 0.030 |
Why?
| | Birefringence | 1 | 1995 | 7 | 0.030 |
Why?
| | Nucleic Acid Heteroduplexes | 1 | 1995 | 9 | 0.030 |
Why?
| | Anticodon | 1 | 1995 | 24 | 0.030 |
Why?
| | Reaction Time | 1 | 2018 | 438 | 0.030 |
Why?
| | Mental Disorders | 1 | 2005 | 1168 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 323 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 594 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1995 | 331 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2026 | 4557 | 0.030 |
Why?
| | Hypotension, Orthostatic | 1 | 2014 | 10 | 0.030 |
Why?
| | Cerebral Ventricles | 2 | 2006 | 54 | 0.030 |
Why?
| | Canada | 1 | 2016 | 428 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7990 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 1406 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2006 | 5868 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1886 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 427 | 0.030 |
Why?
| | Prevalence | 2 | 2014 | 2834 | 0.020 |
Why?
| | Registries | 1 | 2022 | 2385 | 0.020 |
Why?
| | Blood Platelets | 1 | 1997 | 400 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 405 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2014 | 249 | 0.020 |
Why?
| | Video Recording | 1 | 2014 | 212 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1539 | 0.020 |
Why?
| | Base Sequence | 1 | 1995 | 2190 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3671 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 2930 | 0.020 |
Why?
| | Hypertension | 1 | 1999 | 1263 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2117 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 1997 | 621 | 0.020 |
Why?
| | Medication Adherence | 1 | 2015 | 539 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4271 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2027 | 0.020 |
Why?
| | Risk Factors | 2 | 2021 | 10779 | 0.020 |
Why?
| | RNA | 1 | 1995 | 940 | 0.020 |
Why?
| | Genotype | 2 | 2004 | 1833 | 0.020 |
Why?
| | Mice | 1 | 2026 | 18339 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 310 | 0.020 |
Why?
| | Semantics | 1 | 2008 | 100 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 41 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 117 | 0.020 |
Why?
| | Multiple System Atrophy | 1 | 2006 | 8 | 0.020 |
Why?
| | Education | 1 | 2007 | 104 | 0.020 |
Why?
| | Association Learning | 1 | 2007 | 71 | 0.020 |
Why?
| | Polypharmacy | 1 | 2007 | 93 | 0.010 |
Why?
| | Motor Skills | 1 | 2007 | 104 | 0.010 |
Why?
| | Wechsler Scales | 1 | 2006 | 59 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2007 | 421 | 0.010 |
Why?
| | Memory | 1 | 2008 | 295 | 0.010 |
Why?
| | Personality Inventory | 1 | 2006 | 134 | 0.010 |
Why?
| | Bias | 1 | 2006 | 202 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 320 | 0.010 |
Why?
| | Adolescent | 2 | 2019 | 22428 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 2003 | 71 | 0.010 |
Why?
| | Transplants | 1 | 2003 | 39 | 0.010 |
Why?
| | Genetic Counseling | 1 | 2004 | 81 | 0.010 |
Why?
| | Videotape Recording | 1 | 2003 | 37 | 0.010 |
Why?
| | Spinal Cord | 1 | 2005 | 380 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1306 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2003 | 232 | 0.010 |
Why?
| | Inclusion Bodies | 1 | 2002 | 27 | 0.010 |
Why?
| | Cerebellar Diseases | 1 | 2002 | 27 | 0.010 |
Why?
| | Cerebellar Cortex | 1 | 2002 | 20 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1257 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2003 | 191 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 14105 | 0.010 |
Why?
| | California | 1 | 2004 | 475 | 0.010 |
Why?
| | Genetic Markers | 1 | 2002 | 331 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2002 | 307 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2007 | 790 | 0.010 |
Why?
| | Dopamine | 1 | 2003 | 283 | 0.010 |
Why?
| | Central Nervous System | 1 | 2003 | 281 | 0.010 |
Why?
| | Gait | 1 | 2004 | 313 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 844 | 0.010 |
Why?
| | Brain Mapping | 1 | 2003 | 536 | 0.010 |
Why?
| | Facial Nerve | 1 | 1999 | 39 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2002 | 618 | 0.010 |
Why?
| | Patient Selection | 1 | 2003 | 719 | 0.010 |
Why?
| | Health Status | 1 | 2004 | 836 | 0.010 |
Why?
| | Mass Screening | 1 | 2007 | 1347 | 0.010 |
Why?
| | Neurofibrils | 1 | 1997 | 2 | 0.010 |
Why?
| | Electron Transport Complex III | 1 | 1997 | 18 | 0.010 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 1997 | 34 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1997 | 57 | 0.010 |
Why?
| | Electron Transport Complex IV | 1 | 1997 | 62 | 0.010 |
Why?
| | Child | 2 | 2006 | 22633 | 0.010 |
Why?
| | Reference Values | 1 | 1997 | 797 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2730 | 0.000 |
Why?
|
|
Leehey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|